However, precise tumour grading is crucial for improved patient surveillance and treatment, which was emphasised by results from the recently published INDIGO trial showing strong clinical efficacy of the IDH1/2 inhibitor vorasidenib in grade 2 IDH-mutant glioma [26]. This evidence concerns the gene IDH1 and neoplasm.